VRTX Vertex Accounting Capitalization

Vertex Pharmaceuticals (VRTX) production capacities are operating at maximum efficiency thanks to modernized certified lines. Business growth relies on partnerships with genetic engineering laboratories to create innovative therapies. This price chart reflects the stability provided by the company's dominance in cystic fibrosis treatment, generating a steady cash flow of 20.37 driven by constant demand for life-saving medications.

Vertex Pharmaceuticals Incorporated (VRTX) - Company Book Value from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for Vertex (VRTX)

- price and consensus price forecast:

Price Vertex Corp|VRTX - Consensus Target

- market capitalization data:

Market Capitalization Vertex Pharmaceuticals Incorporated|VRTX - Total Company Value

- book capitalization data:

Net Assets per Share Vertex Pharmaceuticals|VRTX - Company Book Value|Market Capitalization to Net Assets vrtx.com|VRTX - Company Total Assets

- debt and liquidity data:

Debt to Capital Vertex Pharmaceuticals|VRTX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Vertex Pharmaceuticals Incorporated|VRTX - Company Aggregate Debts|Debts to Net Assets Vertex Pharmaceuticals Incorporated

Summary company analytics:VRTX - Vertex Corp

Mass-produced product of Vertex Pharmaceuticals Inc.

Professional capital evaluates the profile of Vertex Pharmaceuticals (VRTX) through the lens of tangible assets. The company's book capitalization trend reflects the net asset value minus all liabilities, stripping away market speculation. The growth of this metric confirms the accumulation of hard capital. For Vertex Pharmaceuticals (VRTX), this is based on the ownership of high-tech laboratories in the US. Monopoly status and patent protection make this asset fundamentally resilient.

Competitor analysis for Vertex Pharmaceuticals